Reading this on a mobile device? Try our optimized mobile version here:

November 14, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
Quotient is on a roll with new FDA approvals & GPO contracts
More good news from Quotient! Not only do we have FDA-approved Reagent Red Blood Cells products, but also just approved Rare Antisera, including Anti-s and Anti-Wra. We also have new 3-yr agreements with Premier Inc. and the General Services Administration. Great products and value from the one manufacturer focused on manual testing. Contact us today.

  Science & Health 
  • Researchers use iPS cells to build model for Best disease
    Researchers at the University of Wisconsin's McPherson Eye Research Institute have developed a laboratory model for a genetic form of macular degeneration called Best disease using skin-derived induced pluripotent stem cells. The model provided clues to some of the cellular processes associated with the condition, including the accumulation of old photoreceptor cells and fluid. The findings are set to be published in the journal Human Molecular Genetics. Beloit Daily News (Wis.) (11/12) LinkedInFacebookTwitterEmail this Story
Quality and Process Improvement Solutions are Just a Click Away
AABB Consulting Services can help you meet the requirements of any accrediting organization. Guidance is also available for: implementation plans, process flow, software issues, computer validation, compliance audits, vendor audits and custom projects. For more information, visit our web site or email

  Emerging Trends 
  • Poll shows misconceptions surrounding antibiotic use
    Nine in 10 U.S. adults are aware that antibiotics can treat bacterial infections, but more than a third mistakenly believe that these drugs can cure viral infections, such as the common cold, a CDC poll found. Forty-one percent of the respondents said they had been told very little or nothing at all about antibiotic resistance. HealthDay News (11/13) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  • Texas Biomed gets $2M to develop Chagas' disease test
    A $2 million grant was awarded to the Texas Biomedical Research Institute in San Antonio to develop a test for detecting Chagas' disease. The money is part of a $3 million grant awarded by the Wellcome Trust to the Drugs for Neglected Diseases initiative. "The studies this grant will fund will enable us to determine which of several drugs are most effective at treating the disease," said John VandeBerg, chief scientific officer at Texas Biomed. San Antonio Express-News (11/13) LinkedInFacebookTwitterEmail this Story
  • Prev AbR agrees to send C. difficile program to Synthetic Biologics
    Synthetic Biologics has signed a deal for Prev AbR's clinical-stage and associated beta-lactamase assets for prevention of Clostridium difficile infection. The firm plans to use the compounds to develop and market SYN-004, an experimental oral beta-lactamase enzyme treatment. Given in combination with beta-lactam antibiotics, SYN-004 is designed to protect microscopic organisms in the gastrointestinal tract. Genetic Engineering & Biotechnology News (11/12) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • FDA, state regulators seek tighter oversight of drug compounders
    The FDA and state health regulators called for congressional action to bolster federal oversight of drug compounders as Congress prepared for hearings on a meningitis outbreak tied to the New England Compounding Center. "It is clear that the patchwork of disparate state regulations is not enough to keep the public safe," Massachusetts Department of Public Health interim Commissioner Dr. Lauren Smith wrote in prepared testimony filed with a House oversight panel. "FDA's authority over compounding pharmacies is more limited by law and needs to be strengthened," the FDA said. FDA Commissioner Dr. Margaret Hamburg is set to testify today. Reuters (11/13) LinkedInFacebookTwitterEmail this Story
  • MRSA treatment receives orphan drug status from FDA
    The FDA has given orphan drug status to Savara Pharmaceuticals' inhaled antibiotic AeroVanc, a treatment for pulmonary methicillin-resistant Staphylococcus aureus infection in people with cystic fibrosis. The drug is a dry, powdered formulation of vancomycin. "We hope to provide similar benefits to MRSA infected patients that tobramycin provides for the treatment of Pseudomonas aeruginosa infections," Savara CEO Robert Neville said. Pharmaceutical Business Review Online (11/14) LinkedInFacebookTwitterEmail this Story
  • CMS posts specification sheets for stage 2 MU
    The specification sheets for the second stage of EHR meaningful use have been posted by CMS for eligible hospitals and professionals. The sheets are created to help them calculate the numerator and denominator for every MU objective and judge whether they qualify to be excluded from an objective. Health Data Management (11/12) LinkedInFacebookTwitterEmail this Story
  • Hardship exemption deadline extended by CMS
    CMS has extended its deadline for filing hardship exemptions to avoid Medicare payment penalties next year. CMS-designated groups and qualified professionals can claim the exemption on the CMS website until Jan. 31, 2013. Physicians who do not meet e-prescribing requirements could lose 1.5% of their Medicare payment rates next year without the exemption. Modern Medicine/Medical Economics (11/12) LinkedInFacebookTwitterEmail this Story
  Association News 
  • "Neonatal Transfusion Guidance" Available in AABB Marketplace
    AABB has made "Neonatal Transfusion Guidance" available in its Marketplace. The new publication -- a digital download -- addresses the unique requirements for neonatal transfusion that affect processes and procedures in the continuum from collection and selection of blood components to the methods of administration. Other topics covered include the importance of communication among clinical staff, laboratory personnel and parents of neonates; component processing techniques such as irradiation, filtration and aliquoting; effects of component storage and preservation; and blood administration concerns (e.g., venous access, infusion pumps, blood warming). LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
VP Patient ServicesBlood Centers of the PacificUS - CA - San Francisco
Quality Source ConsultantBlood Systems, Inc.US - Nationwide
Quality SpecialistBlood Systems, Inc.US - NM - Albuquerque
Immunohematology Reference TechnologistLifeStreamUS - CA - San Bernardino
Director, LaboratorySan Diego Blood BankUS - CA - San Diego
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Help Desk SpecialistAABBUS - MD
Staff AccountantAABBUS - MD
Click here to view more job listings.

The best way to find out if you can trust somebody is to trust them."
--Ernest Hemingway,
American author and journalist

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
A powerful website for SmartBrief readers including:
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information